THE World Health Organisation has adjudgedthe antiviral drug Remdesivir inadequate for prevention of ultimate COVID-19 mortalities since its discovery Remdesivi has been touted as one of the most promising COVID-19 treatments, has turned out to do little to prevent deaths from the disease.
Remdesivir, which was part of the experimental cocktail given to US President Donald Trump when he caught the new coronavirus last month, was one of several vaccines reviewed in a large study of more than 11,000 people across 30 countries.
The drug appeared to have little or no effect on hospitalised COVID-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.
According to source, data yet to be peer-reviewed or published in a scientific journal, seems to contradict at least two major US studies that have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.
It will be recalled that Washington authorised the emergency use of the medicine, made by U.S. Pharmaceutical Company, Gilead Sciences and originally intended as a treatment for Ebola on May 1, followed by a range of other countries and the European Union.